Market Overview

4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate

4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate

H.C. Wainwright has initiated bullish coverage of four healthcare stocks headed into the end of 2017. Analyst Edward White explained his positive take on the four stocks in a research note on Thursday. Here’s a rundown of what he had to say.

Acceleron Pharma - Buy

White said the future of Acceleron Pharma Inc (NASDAQ: XLRN) lies in its leading drug candidate, Iuspatercept. Acceleron is currently co-developing the drug with Celgene Corporation (NASDAQ: CELG). H.C. Wainwright is projecting peak sales of $2 billion for Iuspatercept, or roughly $400 million for Acceleron.

“We think luspatercept could be brought to the market by late 2019, and it will achieve blockbuster sales by 2026,” White wrote. H.C. Wainwright has a $57 price target for Acceleron stock.

Fate Therapeutics - Buy

White said Fate Therapeutics Inc (NASDAQ: FATE) has a strong pipeline of best-in-class drug candidates to treat cancer patients and other diseases with major unmet needs. According to White, the company’s leading candidate, ProTmune, has the highest probability of success, but that its NK-100 candidate has the highest upside.

“We project revenues of $329M and $68M for ProTmune and NK-100, respectively, in 2026,” White wrote. H.C. Wainwright has a $7 price target for Fate stock.

Related Link: Express Scripts: Another Potential Amazon Victim?

Mirati Therapeutics - Buy

White said Mirati Therapeutics, Inc. (NASDAQ: MRTX)’s precision oncology strategy will be a winner for long-term investors. Mirati is developing drugs that target specific mutations that are known to cause cancer. The stock recently jumped following positive data presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.

“We note Mirati's products are in early development and project revenues of $210M, $175M, and $140M for glesatinib, sitravatinib, and mocetinostat, respectively, in 2026,” White wrote. H.C. Wainwright has a $20 price target for Mirati stock.


White said TESARO Inc (NASDAQ: TSRO) isn't getting enough credit for its U.S. Zejula launch and the rest of its impressive pipeline. He expects 2018 global revenue of $111 million from Varubi and $379 million from Zejula in 2018.

“We believe the stock’s current trading price serves as an attractive entry point for investors given the untapped potential for Zejula in other indications, including the front-line setting for ovarian cancer and Varubi in chemotherapy-induced nausea and vomiting,” White wrote.

H.C. Wainwright has a $158 price target for TESARO.

Related Link: A Deep Dive Into MannKind's Big Bet On Afrezza

Latest Ratings for XLRN

Oct 2020Morgan StanleyMaintainsOverweight
Aug 2020Credit SuisseMaintainsOutperform
Aug 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for XLRN
View the Latest Analyst Ratings


Related Articles (XLRN + FATE)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas Price Target Initiation Top Stories Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

INTCJP MorganMaintains70.0
STMCanaccord GenuityMaintains47.0
ELDeutsche BankMaintains248.0
UAADeutsche BankMaintains13.0
INTCDeutsche BankMaintains55.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at